| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Red Light Holland Corp: Red Light talks publication of psilocybin clinical trial | 11 | Stockwatch | ||
| Fr | Red Light Holland Corp.: Red Light Holland Highlights Publication of Randomized Clinical Trial Showing a Single Dose of Psilocybin Reduced Cocaine Use, with Filament Health Holding the Exclusive License to the Data and Intellectual Property | 361 | Newsfile | Peer-reviewed results published yesterday (May 7, 2026) in JAMA Network Open demonstrate that a single dose of psilocybin meaningfully reduced cocaine use in adults with cocaine use disorder over... ► Artikel lesen | |
| Do | Red Light Holland Corp: Red Light expands PEX010 distribution in North America | 4 | Stockwatch | ||
| Do | Red Light Holland Corp.: Red Light Holland's Wholly Owned Subsidiary, Filament Health, Expands Distribution of PEX010 Across Canadian and U.S. Research Institutions | 372 | Newsfile | Toronto, Ontario--(Newsfile Corp. - May 7, 2026) - Red Light Holland Corp. (CSE: TRIP) (OTCQB: TRUFF) (FSE: 4YX) ("Red Light" or the "Company") is an Ontario-based organization advancing innovation... ► Artikel lesen | |
| 05.05. | Red Light Holland Corp: Red Light plans rebranding, including name change | 3 | Stockwatch | ||
| 30.04. | Red Light Holland Corp: Red Light Holland closes Filament Health acquisition | 5 | Stockwatch | ||
| RED LIGHT HOLLAND Aktie jetzt für 0€ handeln | |||||
| 30.04. | Red Light Holland Corp.: Red Light Holland Completes Acquisition of Filament Health, Creating a Global Leader in Psychedelic Drug Development, Commercialization and Distribution | 353 | Newsfile | Establishes a vertically integrated platform spanning pharmaceutical-grade botanical drug development and global consumer distributionAdds Filament's extensive intellectual property portfolio, including... ► Artikel lesen | |
| 29.04. | Red Light Holland Corp: Red Light Holland receives court OK for Filament buy | 5 | Stockwatch | ||
| 29.04. | Red Light Holland Corp.: Red Light Holland Announces Filament Health Obtains Final Order for Proposed Arrangement | 326 | Newsfile | Toronto, Ontario--(Newsfile Corp. - April 29, 2026) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light" or the "Company") and Filament Health Corp. (OTC: FLHLF) ("Filament")... ► Artikel lesen | |
| 27.04. | Red Light Holland Corp: Red Light target Filament receives shareholder approval | 2 | Stockwatch | ||
| 27.04. | Red Light Holland Corp.: Red Light Holland Announces Filament Health Shareholder Approval of Acquisition | 328 | Newsfile | Toronto, Ontario--(Newsfile Corp. - April 27, 2026) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light") and Filament Health Corp. (OTC: FLHLF) ("Filament") are pleased... ► Artikel lesen | |
| 24.04. | Red Light Holland Corp: Red Light target talks PEX010 clinical supply shipments | 6 | Stockwatch | ||
| 24.04. | Red Light Holland Corp.: Red Light Holland Showcases Growing Clinical Demand for Filament Health's PEX010 with New and Repeat University Shipments | 397 | Newsfile | Toronto, Ontario--(Newsfile Corp. - April 24, 2026) - Red Light Holland Corp. (CSE: TRIP) (OTCQB: TRUFF) (FSE: 4YX) ("Red Light" or the "Company") is pleased to highlight continued expansion and... ► Artikel lesen | |
| 21.04. | Red Light Holland Corp: Red Light notes psychedelic policy shift for Kala Bio | 30 | Stockwatch | ||
| 21.04. | Red Light Holland Corp: Red Light notes publication points to repeatable models | 8 | Stockwatch | ||
| 20.04. | Red Light Holland Corp.: Red Light Holland Highlights U.S. FDA-Authorized Study Supporting Multi-Session Psilocybin Therapy using Filament Health's Patented PEX010 Botanical Drug Candidate | 374 | Newsfile | Study conducted under U.S. FDA Investigational New Drug (IND) authorization by Dr. Anthony Back at the University of WashingtonSecond psilocybin session showed meaningful improvements in anxiety... ► Artikel lesen | |
| 07.04. | Red Light Holland Corp: Red Light target expands PEX010 clinical network | 12 | Stockwatch | ||
| 07.04. | Red Light Holland Corp.: Red Light Holland Reports Continued Expansion of Filament Health's PEX010 Clinical Network with New License Agreements and Research Shipments | 525 | Newsfile | Three new license agreements signed and two research shipments completed in March 2026, spanning institutions in Australia, the United Kingdom, and CanadaToronto, Ontario--(Newsfile Corp. - April... ► Artikel lesen | |
| 02.04. | Red Light Holland Corp: Red Light to support Carhart-Harris Lab for study | 7 | Stockwatch | ||
| 01.04. | Red Light Holland Corp.: Red Light Holland to Support University of California San Francisco's Global Psychedelic Study Through Filament Health's Clinical Network | 573 | Newsfile | Toronto, Ontario--(Newsfile Corp. - April 1, 2026) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light" or the "Company") today announced that, through Filament Health Corp.... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BAYER | 38,440 | +3,67 % | Bayer zahlt bis zu 2,45 Milliarden Dollar für Übernahme im Bereich Augenheilkunde | Der DAX-notierte Bayer-Konzern übernimmt Perfuse Therapeutics vollständig und sichert sich damit die weltweiten Rechte an PER-001, einem niedermolekularen Endothelinrezeptor-Antagonisten in der klinischen... ► Artikel lesen | |
| NOVO NORDISK | 39,655 | -0,51 % | Novo-Nordisk-Aktie: Geht jetzt plötzlich alles ganz schnell? | Über Wochen und Monate hinweg war die Aktie von Novo Nordisk abgemeldet. Jetzt blickt sie auf ein bemerkenswertes Comeback zurück. Kann dieses anhalten? Novo Nordisk nach den Zahlen: Spürbare Erleichterung!... ► Artikel lesen | |
| NOVARTIS | 126,02 | -0,03 % | Biotech und die Effizienz-Revolution: Warum für Novartis, BioNTech und BioNxt die letzte Meile entscheidet | Während für Biotech-Investoren über Jahrzehnte hinweg das Dogma galt, dass nur die Entdeckung eines völlig neuen Moleküls den Weg zu einem Milliarden-Exit ebnen kann, zeigt die Realität des Marktes... ► Artikel lesen | |
| AURORA CANNABIS | 2,882 | +0,56 % | AURORA CANNABIS INC: Ruhe vor dem nächsten Impuls | ||
| SANOFI | 73,47 | +0,10 % | Mesoblast Aktie: Warum sich der Blick auf diesen Biotech-Player jetzt lohnt - und was Anleger von Merck, Regeneron & Co. lernen können | ||
| GSK | 21,790 | +2,06 % | GSK findet für neues Hepatitis-Medikament Vertriebspartner in China | DJ GSK findet für neues Hepatitis-Medikament Vertriebspartner in China
Von Adria Calatayud
DOW JONES--GSK kooperiert mit Sino Biopharmaceutical, um die Markteinführung für sein Hepatitis-B-Medikament... ► Artikel lesen | |
| CANOPY GROWTH | 0,940 | +0,94 % | CANOPY GROWTH CORPORATION: Struktur vor Impuls | ||
| STADA ARZNEIMITTEL | - | - | Enzymatica AB: Quarterly report Q1/2026 - Enzymatica strengthens international position through STADA agreement | First quarter
Net sales amounted to SEK 11.4 million (12.3).
Operating result amounted to SEK -13.6.million (-18.0)
Earnings per share, before... ► Artikel lesen | |
| ELI LILLY | 843,00 | -0,04 % | Eli Lilly, Compass Pathways und das Nadelöhr der Psychiatrie: Emyria Limited lanciert globale Infrastruktur-Lösung | ||
| TILRAY BRANDS | 4,610 | -0,11 % | Tilray Brands Inc (2): Tilray Brands' Blue Point rolls out Magic Hour IPA | ||
| TEVA | 30,400 | -0,65 % | Teva Pharm Q1 2026: Innovatives Portfolio wächst um 41 %, Emalex-Übernahme angekündigt | ||
| VERTEX PHARMACEUTICALS | 381,60 | -0,08 % | Vertex Pharmaceuticals Incorporated: Vertex Announces CASGEVY Reimbursement Agreement for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia in Germany | -The agreement ensures sustainable access to this innovative therapy for eligible patients ages 12 years and older in Germany- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today... ► Artikel lesen | |
| INNOCAN PHARMA | 3,220 | 0,00 % | Breaking News: Schmerzfrei ohne Nebenwirkung?! - Fachblatt berichtet! | ||
| MPH HEALTH CARE | 21,900 | +0,46 % | Original-Research: MPH Health Care AG (von First Berlin Equity Research GmbH): Kaufen | Original-Research: MPH Health Care AG - from First Berlin Equity Research GmbH
05.05.2026 / 11:57 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The issuer... ► Artikel lesen | |
| CRONOS GROUP | 2,330 | -1,10 % | Cronos Group Inc.: Cronos Group Reports 2026 First Quarter Results | Net revenue in Q1 2026 increased by 40% year-over-year to $45.2 million Achieved record net revenue and gross profit in Q1 2026 Reached #1 market share in vapes in Canada1 Ninth consecutive quarter... ► Artikel lesen |